Epstein-Barr Virus (EBV) reactivation and EBV-related post-transplant lymphoproliferative disease (PTLD) have emerged as a severe complication after stem cell transplantation (SCT). We prospectively evaluated 104 consecutive patients receiving SCT either autologous or allogeneic. Fifty-two patients (50%) presented EBV DNA-emia and five of them developed PTLD proven or probable. PTLD rate was 9.6% among patients with EBV DNA-emia. One patient developed PTLD without EBV DNA-emia (0.96%). Overall PTLD incidence was 5.7%. No PTLD developed after autologous SCT. EBV DNA-emia was significantly more frequent after allogeneic than autologous SCT (60.7% vs 17.4%, p = 0.0002). At EBV reactivation, serum protein electrophoresis and immunofixation were assessed. Global incidence of γ-peak after allogeneic SCT with EBV reactivation was 65.3% (32/49 patients) and monoclonal gammopathy (MG) was identified in 23/28 evaluable patients (82%). All patients with PTLD developed γ-peak and in five of them MG was identified. MG is consistently associated with EBV DNA-emia and may help identification of progression to PTLD after allogeneic SCT.

Chiusolo, P., Metafuni, E., Cattani, P., Piccirillo, N., Santangelo, R., Manzara, S., Bellesi, S., De Michele, T., Leone, G., Sica, S., Prospective evaluation of Epstein-Barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy., <<JOURNAL OF CLINICAL IMMUNOLOGY>>, 2010; 30 (6): 894-902 [http://hdl.handle.net/10807/15187]

Prospective evaluation of Epstein-Barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy.

Chiusolo, Patrizia;Cattani, Paola;Piccirillo, Nicola;Santangelo, Rosaria;Manzara, Stefania;Bellesi, Silvia;De Michele, Teresa;Leone, Giuseppe;Sica, Simona
2010

Abstract

Epstein-Barr Virus (EBV) reactivation and EBV-related post-transplant lymphoproliferative disease (PTLD) have emerged as a severe complication after stem cell transplantation (SCT). We prospectively evaluated 104 consecutive patients receiving SCT either autologous or allogeneic. Fifty-two patients (50%) presented EBV DNA-emia and five of them developed PTLD proven or probable. PTLD rate was 9.6% among patients with EBV DNA-emia. One patient developed PTLD without EBV DNA-emia (0.96%). Overall PTLD incidence was 5.7%. No PTLD developed after autologous SCT. EBV DNA-emia was significantly more frequent after allogeneic than autologous SCT (60.7% vs 17.4%, p = 0.0002). At EBV reactivation, serum protein electrophoresis and immunofixation were assessed. Global incidence of γ-peak after allogeneic SCT with EBV reactivation was 65.3% (32/49 patients) and monoclonal gammopathy (MG) was identified in 23/28 evaluable patients (82%). All patients with PTLD developed γ-peak and in five of them MG was identified. MG is consistently associated with EBV DNA-emia and may help identification of progression to PTLD after allogeneic SCT.
Inglese
Chiusolo, P., Metafuni, E., Cattani, P., Piccirillo, N., Santangelo, R., Manzara, S., Bellesi, S., De Michele, T., Leone, G., Sica, S., Prospective evaluation of Epstein-Barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy., <>, 2010; 30 (6): 894-902 [http://hdl.handle.net/10807/15187]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/15187
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact